2004
DOI: 10.1210/jc.2003-031457
|View full text |Cite
|
Sign up to set email alerts
|

Effect of Growth Hormone Treatment on Adult Height in Peripubertal Children with Idiopathic Short Stature: A Randomized, Double-Blind, Placebo-Controlled Trial

Abstract: GH is often used to treat children with idiopathic short stature despite the lack of definitive, long-term studies of efficacy. We performed a randomized, double-blind, placebo-controlled trial to determine the effect of GH on adult height in peripubertal children. Subjects (n = 68; 53 males and 15 females), 9-16 yr old, with marked, idiopathic short stature [height or predicted height < or = -2.5 sd score (SDS)] received either GH (0.074 mg/kg) or placebo sc three times per week until they were near adult hei… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

14
162
3
5

Year Published

2004
2004
2017
2017

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 202 publications
(184 citation statements)
references
References 50 publications
14
162
3
5
Order By: Relevance
“…Other studies have addressed similar questions and have obtained quite similar results (33,34). Altogether, these results demonstrate that GH given alone can increase the pubertal growth spurt in short adolescents.…”
Section: Gh In Short Children At Onset Of Pubertysupporting
confidence: 71%
“…Other studies have addressed similar questions and have obtained quite similar results (33,34). Altogether, these results demonstrate that GH given alone can increase the pubertal growth spurt in short adolescents.…”
Section: Gh In Short Children At Onset Of Pubertysupporting
confidence: 71%
“…Twenty studies related to the effect of treatment with growth hormone on the adult height of children with ISS with a total sample size of 1,517 were included in the meta-analysis ( Fig. 1 and Table 1 [10,11,[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] When results of studies were combined using random effects model, SMD for treatment start height was -1.64 (95% CI: -2.01 to -1.28) which is equal to 5% (their height was higher than 5% of participants) (Fig. 3).…”
Section: Resultsmentioning
confidence: 99%
“…Secondary IGFD has thus been associated with a variety of genetic, developmental defects in pituitary development and GH secretion, while primary IGFD has been observed with molecular defects involving the GH receptor (GHR), the GHR signaling cascade, and the IGF-I gene itself. Since studies suggest that at least 25% of children labeled as ISS have low serum IGF-I, despite apparently normal GH secretion, these rare genetic causes of primary IGFD, at least in their classical form, are likely to account for only a small percentage of patients identified as primary IGFD (2,3,5,6). A further explanation for such cases is necessary, and possibilities include: i) heterozygosity for specific mutations affecting the GH-IGF axis, accompanied by inadequate compensation at the level of GH production or IGF-I gene transcription and production; ii) polymorphisms of known genes of the GH-IGF axis, affecting their transcription or translation; iii) defects involving genes as yet unidentified; or iv) combinations of the factors listed above.…”
Section: How Do We Explain Short Stature?mentioning
confidence: 99%